Context Therapeutics (NASDAQ:CNTX) CEO Martin Lehr joined Proactive's Stephen Gunnion with details of a clinical trial collaboration and supply agreement with The Menarini Group for Menarini’s oral selective estrogen receptor degrader (SERD), elacestrant.
Lehr explained that the collaboration with Menarini will explore the therapeutic potential of adding ONA-XR, Context's oral progesterone receptor antagonist, to elacestrant.
"This is an agreement we've been working on for some time and we're very excited about it," Lehr said. "We think it will be an incredible positive for the company; an incredible positive for patients."